Investor Presentaiton

Changes to the Development Pipeline Phase I Phase II New or Phase ◆BCL6 LDD in Lymphoma Transition Removed ✦NME 2 +CD47xCD20 +GSPT1 CELMOD (CC-90009) RIPK1 Inhibitor * Partner-run study; NME leading indication; # BMS territory Ill Bristol Myers Squibb™ + Anti-TIGIT +HSP47 Data as of September 14th, 2023 Phase III +LPA1 Antagonist in IPF LPA1 Antagonist in PPF ✦obexelimab*# in IgG4- Related Disease Registrational Submissions Oncology Hematology CV Immunology Neuroscience Approvals (n=2) • OPDIVO in Adj Melanoma (EU) REBLOZYL in 1L MDS associated anemia (US) Not for Product Promotional Use 147

View entire presentation